PT Bio Farma
- Country
- 🇮🇩Indonesia
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.biofarma.co.id
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
- Conditions
- Vaccine Adverse ReactionVaccine Reaction
- Interventions
- Biological: SARS-CoV-2 Protein Subunit Recombinant VaccineBiological: Active Comparator
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 1050
- Registration Number
- NCT05546502
- Locations
- 🇮🇩
Bali Mandara Hospital, Denpasar, Bali, Indonesia
🇮🇩Abdoel Moeloek Hospital, Bandar Lampung, Lampung, Indonesia
🇮🇩Universitas Udayana Hospital, Denpasar, Bali, Indonesia
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
- Conditions
- COVID-19
- Interventions
- Biological: Active ComparatorBiological: SARS-CoV-2 subunit protein recombinant vaccine
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 900
- Registration Number
- NCT05525208
- Locations
- 🇮🇩
Faculty of Medicine Universitas Padjadjaran, Bandung, West Java, Indonesia
🇮🇩Faculty of Medicine Universitas Udayana, Denpasar, Bali, Indonesia
Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)
- Conditions
- Vaccine ReactionVaccine Adverse Reaction
- Interventions
- Biological: Hepatitis B vaccine lot 3Biological: Hepatitis B vaccine lot 1Biological: Hepatitis B vaccine lot 2Biological: Hepatitis B vaccine (registered)
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 540
- Registration Number
- NCT05482295
Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)
- Conditions
- Diphtheria Vaccine Adverse ReactionHepatitis B Vaccine Adverse ReactionTetanus Vaccine Adverse ReactionPertussis Vaccine Adverse ReactionHaemophilus Influenzae Type B Vaccine Adverse Reaction
- Interventions
- Biological: Recombinant Hepatitis B new Bulk vaccineBiological: Recombinant Hepatitis B vaccine (Registered BioFarma)Biological: DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccineBiological: Pentabio
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 220
- Registration Number
- NCT05482282
- Locations
- 🇮🇩
Garuda Primary Health Centre, Bandung, West Java, Indonesia
🇮🇩Ibrahim Adjie Primary Health Centre, Bandung, West Java, Indonesia
🇮🇩Puter Primary Health Centre, Bandung, West Java, Indonesia
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
- Conditions
- COVID-19
- Interventions
- Biological: COVID-19 Protein Subunit Recombinant VaccineBiological: Active Comparator
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 4050
- Registration Number
- NCT05433285
- Locations
- 🇮🇩
Faculty of Medicine Diponegoro University, Semarang, Central Java, Indonesia
🇮🇩Fakultas Kedokteran Universitas Indonesia, Jakarta, Greater Jakarta, Indonesia
🇮🇩Faculty of Medicine Universitas Hassanudin, Makassar, South Sulawesi, Indonesia
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine
- Conditions
- COVID-19
- Interventions
- Biological: placeboBiological: SARS-CoV-2 protein subunit recombinant vaccine
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 360
- Registration Number
- NCT05313035
- Locations
- 🇮🇩
Faculty of Medicine, Diponegoro University, Semarang, Semarang, Central Java, Indonesia
🇮🇩Faculty of Medicine Universitas Hassanudin, Makassar, South Sulawesi, Indonesia
🇮🇩Faculty of Medicine, Universitas Andalas, Padang, Padang, West Sumatera, Indonesia
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018
- Conditions
- COVID-19
- Interventions
- Biological: SARS-CoV-2 inactivated vaccineBiological: SARS-CoV-2 protein subunit recombinant vaccine
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 175
- Registration Number
- NCT05228613
- Locations
- 🇮🇩
Faculty of Medicine, Diponegoro University, Semarang, Semarang, Central Java, Indonesia
🇮🇩Fakultas Kedokteran Universitas Indonesia, Jakarta, Greater Jakarta, Indonesia
Safety and Tuberculin Conversion Following BCG Vaccination
- Conditions
- BCG Vaccination Reaction
- Interventions
- Biological: BCG ampoule vaccineBiological: BCG vial vaccine
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 220
- Registration Number
- NCT05124340
- Locations
- 🇮🇩
Puskesmas Cerme, Gresik, Jawa Timur, Indonesia
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine
- Conditions
- Covid19
- Interventions
- Biological: SARS-CoV-2 Protein Subunit Recombinant VaccineBiological: SARS-CoV-2 Inactivated Vaccine
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 54
- Registration Number
- NCT05067894
- Locations
- 🇮🇩
Fakultas Kedokteran Universitas Indonesia, Jakarta, Greater Jakarta, Indonesia
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
- Conditions
- Safety Issues
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 1100
- Registration Number
- NCT05037227
- Locations
- 🇮🇩
Jakarta Provincial Ministry of Health, Jakarta, DKI Jakarta, Indonesia